The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...

During early germination, water uptake activates metabolic pathways that stimulate the production of hydrolytic enzymes like ...

The FDA approved narsoplimab-wuug as the first targeted treatment for transplant-associated thrombotic microangiopathy in adults and children. On December 24, 2025, the FDA approved narsoplimab-wuug ...

What Is Yartemlea, and Why Does It Matter? Yartemlea (narsoplimab-wuug) is a new medicine approved by the FDA for treating a rare and serious condition called transplant-associated thrombotic ...

Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA ® (narsoplimab-wuug), the first and only therapy indicated for ...

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...

Omeros Corporation has surged after out-licensing zaltenibart to Novo Nordisk, securing $340 million upfront and near-term milestones, with potential for $2.1 billion in additional payments. The deal ...

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing ...